Salim Abdool Karim

Salim Abdool Karim Salim S. Abdool Karim, MBChB, MMed, MS(Epi), FFPHM, FFPath (Virol), DipData, PhD, DSc(hc), FRS is a South African public health physician, epidemiologist and virologist who has played a leading role in the AIDS and COVID-19 pandemic. His scientific contributions have impacted the landscape of HIV prevention and treatment, saving thousands of lives. Provided by Wikipedia
Showing 1 - 20 results of 21 for search 'Salim Abdool Karim', query time: 0.06s Refine Results
  1. 1
    Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists.

    Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. by Muki S Shey, Niren Maharaj, Derseree Archary, Sinaye Ngcapu, Nigel Garrett, Salim Abdool Karim, Jo-Ann S Passmore

    Published 2016-01-01
    Get full text
    Article
  2. 2
    Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?

    Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? by Glenda E Gray, Fatima Laher, Tanya Doherty, Salim Abdool Karim, Scott Hammer, John Mascola, Chris Beyrer, Larry Corey

    Published 2016-03-01
    Get full text
    Article
  3. 3
    COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats

    COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats by Peter J Hotez, Lois Privor-Dumm, Melanie Saville, Jerome H Kim, Sarah Gilbert, Salim Abdool-Karim, Didi Thompson, Jean-Louis Excler

    Published 2023-06-01
    Get full text
    Article
  4. 4
    Factors, enablers and challenges for COVID-19 vaccine development

    Factors, enablers and challenges for COVID-19 vaccine development by Peter J Hotez, Lois Privor-Dumm, Melanie Saville, Jerome H Kim, Sarah Gilbert, Salim Abdool-Karim, Didi Thompson, Jean-Louis Excler

    Published 2023-06-01
    Get full text
    Article
  5. 5
    Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women.

    Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. by Vineet Joag, Aida Sivro, Nonhlanhla Yende-Zuma, Hajra Imam, Natasha Samsunder, Quarraisha Abdool Karim, Salim Abdool Karim, Lyle McKinnon, Rupert Kaul

    Published 2018-01-01
    Get full text
    Article
  6. 6
    High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa

    High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa by Nokukhanya Msomi, Kogieleum Naidoo, Nonhlanhla Yende-Zuma, Nesri Padayatchi, Kerusha Govender, Jerome Amir Singh, Salim Abdool-Karim, Quarraisha Abdool-Karim, Koleka Mlisana

    Published 2020-11-01
    Get full text
    Article
  7. 7
    Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy

    Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy by Fatoumatta Darboe, Stanley Kimbung Mbandi, Kogieleum Naidoo, Kogieleum Naidoo, Nonhlanhla Yende-Zuma, Nonhlanhla Yende-Zuma, Lara Lewis, Ethan G. Thompson, Fergal J. Duffy, Michelle Fisher, Elizabeth Filander, Michele van Rooyen, Nicole Bilek, Simbarashe Mabwe, Lyle R. McKinnon, Lyle R. McKinnon, Novel Chegou, Andre Loxton, Gerhard Walzl, Gerard Tromp, Gerard Tromp, Nesri Padayatchi, Nesri Padayatchi, Dhineshree Govender, Mark Hatherill, Salim Abdool Karim, Salim Abdool Karim, Salim Abdool Karim, Daniel E. Zak, Adam Penn-Nicholson, Thomas J. Scriba, The SATVI Clinical Immunology Team

    Published 2019-06-01
    Get full text
    Article
  8. 8
    High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa.

    High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. by Kogieleum Naidoo, Razia Hassan-Moosa, Nonhlanhla Yende-Zuma, Dhineshree Govender, Nesri Padayatchi, Halima Dawood, Rochelle Nicola Adams, Aveshen Govender, Tilagavathy Chinappa, Salim Abdool-Karim, Quarraisha Abdool-Karim

    Published 2017-01-01
    Get full text
    Article
  9. 9
    Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway

    Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway by Dieter Mielke, Gama Bandawe, Justin Pollara, Melissa-Rose Abrahams, Tinashe Nyanhete, Penny L. Moore, Penny L. Moore, Penny L. Moore, Penny L. Moore, Ruwayhida Thebus, Nicole L. Yates, John C. Kappes, John C. Kappes, Christina Ochsenbauer, Nigel Garrett, Nigel Garrett, Salim Abdool Karim, Salim Abdool Karim, Georgia D. Tomaras, David Montefiori, Lynn Morris, Lynn Morris, Lynn Morris, Lynn Morris, Guido Ferrari, Carolyn Williamson, Carolyn Williamson, Carolyn Williamson

    Published 2019-12-01
    Get full text
    Article
  10. 10
    ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection

    ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection by Dieter Mielke, Gama Bandawe, Jie Zheng, Jennifer Jones, Melissa-Rose Abrahams, Valerie Bekker, Christina Ochsenbauer, Nigel Garrett, Salim Abdool Karim, Penny L. Moore, Lynn Morris, David Montefiori, Colin Anthony, Guido Ferrari, Carolyn Williamson

    Published 2021-11-01
    Get full text
    Article
  11. 11
    CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

    CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subderma... by Cheryl Baxter, Nonhlanhla Yende Zuma, Natasha Samsunder, Salim Abdool Karim, Catherine Hankins, Quarraisha Abdool Karim, Bruno Pozzetto, Leila Mansoor, Tanuja Narayansamy Gengiah, Ishana Harkoo, Precious Radebe, B Maharaj, Marc M Baum, John A Moss

    Published 2022-01-01
    Get full text
    Article
  12. 12
    Field evaluations of four SARS-CoV-2 rapid antigen tests during SARS-CoV-2 Delta variant wave in South Africa

    Field evaluations of four SARS-CoV-2 rapid antigen tests during SARS-CoV-2 Delta variant wave in South Africa by Natasha Samsunder, Gila Lustig, Slindile Ngubane, Thando Glory Maseko, Santhuri Rambaran, Sinaye Ngcapu, Stanley Nzuzo Magini, Lara Lewis, Cherie Cawood, Ayesha B. M. Kharsany, Quarraisha Abdool Karim, Salim Abdool Karim, Kogieleum Naidoo, Aida Sivro

    Published 2023-07-01
    Get full text
    Article
  13. 13
    Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.

    Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. by Denis R Chopera, Zenda Woodman, Koleka Mlisana, Mandla Mlotshwa, Darren P Martin, Cathal Seoighe, Florette Treurnicht, Debra Assis de Rosa, Winston Hide, Salim Abdool Karim, Clive M Gray, Carolyn Williamson, CAPRISA 002 Study Team

    Published 2008-03-01
    Get full text
    Article
  14. 14
    HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.

    HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 spec... by Kelly E Seaton, Lamar Ballweber, Audrey Lan, Michele Donathan, Sean Hughes, Lucia Vojtech, M Anthony Moody, Hua-Xin Liao, Barton F Haynes, Christine G Galloway, Barbra A Richardson, Salim Abdool Karim, Charlene S Dezzutti, M Juliana McElrath, Georgia D Tomaras, Florian Hladik

    Published 2014-01-01
    Get full text
    Article
  15. 15
    The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus.

    The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus. by Sarah B Joseph, Melissa-Rose Abrahams, Matthew Moeser, Lynn Tyers, Nancie M Archin, Olivia D Council, Amy Sondgeroth, Ean Spielvogel, Ann Emery, Shuntai Zhou, Deelan Doolabh, Sherazaan D Ismail, Salim Abdool Karim, David M Margolis, Sergei Kosakovsky Pond, Nigel Garrett, Ronald Swanstrom, Carolyn Williamson

    Published 2024-02-01
    Get full text
    Article
  16. 16
    Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

    Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol... by Nigel Garrett, Sharana Mahomed, Edmund Capparelli, Cheryl Baxter, Tanuja Gengiah, Derseree Archary, Penny Moore, Natasha Samsunder, Dan H Barouch, John Mascola, Julie Ledgerwood, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Quarraisha A Karim, Nonhlanhla Y Zuma, Carolyn Williamson, Patricia E Fast, Bruno Pozzetto, Kevin Carlton, Nicole Doria-Rose

    Published 2020-11-01
    Get full text
    Article
  17. 17
    Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

    Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. by Kshitij Wagh, Tanmoy Bhattacharya, Carolyn Williamson, Alex Robles, Madeleine Bayne, Jetta Garrity, Michael Rist, Cecilia Rademeyer, Hyejin Yoon, Alan Lapedes, Hongmei Gao, Kelli Greene, Mark K Louder, Rui Kong, Salim Abdool Karim, Dennis R Burton, Dan H Barouch, Michel C Nussenzweig, John R Mascola, Lynn Morris, David C Montefiori, Bette Korber, Michael S Seaman

    Published 2016-03-01
    Get full text
    Article
  18. 18
    Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

    Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAP... by Nigel Garrett, Farzana Osman, Sharana Mahomed, Edmund Capparelli, Nonhlanhla Yende Zuma, Derseree Archary, Penny Moore, Natasha Samsunder, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Carolyn Williamson, Bruno Pozzetto, Kevin Carlton, Richard A Koup, Quarraisha Abdool Karim, Leila Mansoor, Tanuja Narayansamy Gengiah, Ishana Harkoo, Precious Radebe, Izukanji T Sikazwe, Disebo Potloane, Nqobile Myeni, Nicole Doria Rose, Lucio Gama, Sandeep Narpala, Leonid Serebryannyy

    Published 2023-08-01
    Get full text
    Article
  19. 19
    V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity

    V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity by Charmaine van Eeden, Constantinos Kurt Wibmer, Cathrine Scheepers, Simone I. Richardson, Molati Nonyane, Bronwen Lambson, Nonhlanhla N. Mkhize, Balakrishnan Vijayakumar, Zizhang Sheng, Sherry Stanfield-Oakley, Jinal N. Bhiman, Valerie Bekker, Tandile Hermanus, Batsirai Mabvakure, Arshad Ismail, M. Anthony Moody, Kevin Wiehe, Nigel Garrett, Salim Abdool Karim, Heini Dirr, Manuel A. Fernandes, Yasien Sayed, Lawrence Shapiro, Guido Ferrari, Barton F. Haynes, Penny L. Moore, Lynn Morris

    Published 2018-12-01
    Get full text
    Article
  20. 20
    Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

    Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. by Cecilia Rademeyer, Bette Korber, Michael S Seaman, Elena E Giorgi, Ruwayhida Thebus, Alexander Robles, Daniel J Sheward, Kshitij Wagh, Jetta Garrity, Brittany R Carey, Hongmei Gao, Kelli M Greene, Haili Tang, Gama P Bandawe, Jinny C Marais, Thabo E Diphoko, Peter Hraber, Nancy Tumba, Penny L Moore, Glenda E Gray, James Kublin, M Juliana McElrath, Marion Vermeulen, Keren Middelkoop, Linda-Gail Bekker, Michael Hoelscher, Leonard Maboko, Joseph Makhema, Merlin L Robb, Salim Abdool Karim, Quarraisha Abdool Karim, Jerome H Kim, Beatrice H Hahn, Feng Gao, Ronald Swanstrom, Lynn Morris, David C Montefiori, Carolyn Williamson

    Published 2017-09-01
    Get full text
    Article

Search Tools: